Guggenheim Issues Pessimistic Forecast for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR) had its price target lowered by investment analysts at Guggenheim from $275.00 to $235.00 in a research report issued on Wednesday, MarketBeat reports. The brokerage currently has a “buy” rating on the conglomerate’s stock. Guggenheim’s target price points to a potential upside of 31.49% from the company’s current price.

A number of other equities research analysts have also issued reports on the stock. KeyCorp reissued an “overweight” rating on shares of Danaher in a research note on Thursday, January 29th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Danaher in a report on Thursday, January 29th. Argus set a $265.00 price target on shares of Danaher in a report on Wednesday, January 14th. TD Cowen cut their price target on shares of Danaher from $270.00 to $245.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Finally, Wolfe Research cut their price target on shares of Danaher from $260.00 to $230.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Danaher has an average rating of “Moderate Buy” and a consensus price target of $242.45.

Danaher Trading Down 2.9%

Shares of NYSE:DHR opened at $178.72 on Wednesday. The firm has a fifty day moving average of $196.45 and a two-hundred day moving average of $214.10. The firm has a market capitalization of $126.49 billion, a P/E ratio of 34.57, a price-to-earnings-growth ratio of 2.50 and a beta of 0.95. Danaher has a 12-month low of $175.00 and a 12-month high of $242.80. The company has a quick ratio of 1.51, a current ratio of 1.87 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. The company had revenue of $5.95 billion during the quarter, compared to analyst estimates of $6 billion. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The company’s revenue for the quarter was up 3.7% on a year-over-year basis. During the same quarter last year, the business posted $1.88 EPS. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. On average, equities analysts expect that Danaher will post 8.4 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Gregory M. Milosevich sold 1,320 shares of Danaher stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $208.01, for a total value of $274,573.20. Following the transaction, the executive vice president owned 5,099 shares in the company, valued at $1,060,642.99. This trade represents a 20.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 10.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Premier Path Wealth Partners LLC raised its holdings in Danaher by 3.1% in the 1st quarter. Premier Path Wealth Partners LLC now owns 2,551 shares of the conglomerate’s stock worth $484,000 after acquiring an additional 76 shares during the period. Granite Harbor Advisors Inc. raised its holdings in Danaher by 17.4% in the 1st quarter. Granite Harbor Advisors Inc. now owns 1,142 shares of the conglomerate’s stock worth $217,000 after acquiring an additional 169 shares during the period. Folger Nolan Fleming Douglas Capital Management Inc. raised its holdings in Danaher by 13.0% in the 1st quarter. Folger Nolan Fleming Douglas Capital Management Inc. now owns 4,205 shares of the conglomerate’s stock worth $797,000 after acquiring an additional 485 shares during the period. SJS Investment Consulting Inc. raised its holdings in Danaher by 202.2% in the 1st quarter. SJS Investment Consulting Inc. now owns 281 shares of the conglomerate’s stock worth $53,000 after acquiring an additional 188 shares during the period. Finally, Simmons Bank raised its holdings in Danaher by 9.4% in the 1st quarter. Simmons Bank now owns 29,908 shares of the conglomerate’s stock worth $5,671,000 after acquiring an additional 2,581 shares during the period. Institutional investors own 79.05% of the company’s stock.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q1 EPS beat and slight raise to FY EPS range — Danaher beat non‑GAAP EPS estimates ($2.06 vs. consensus) and nudged full‑year adjusted EPS guidance higher, which supports earnings visibility. Earnings Call Highlights
• Positive Sentiment: Bioprocessing momentum and M&A strategy remain drivers — management highlighted strength in bioprocessing and the acquisition pipeline as long‑term growth levers. Q1 Deep Dive
• Neutral Sentiment: Large euro‑denominated senior‑notes offering (~€2.98B net proceeds) — the deal finances operations and transactions but increases liabilities; market reaction depends on how proceeds are used. Notes Offering
• Neutral Sentiment: Masimo acquisition: longer‑term optionality vs. near‑term integration/earnings pressure — analysts note the deal adds strategic upside but may weigh on near‑term returns and capital allocation. Masimo Analysis
• Negative Sentiment: $172.5M shareholder settlement over post‑pandemic demand disclosures — a material cash charge and reputational headwind that increases near‑term litigation/expense risk. Settlement Report
• Negative Sentiment: Revenue miss and Diagnostics softness weighed on the print — core revenue growth was modest and Diagnostics showed weakness (lighter respiratory season at Cepheid), which undercut the EPS beat. Revenue/Segment Notes
• Negative Sentiment: Multiple analyst price‑target cuts (Morgan Stanley, JPMorgan, Wells Fargo, Guggenheim, UBS among others) — downgrades and lower targets increase downside pressure and reduce near‑term analyst support. Morgan Stanley PT Cut

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.